{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:12:50Z","timestamp":1782166370992,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12325-023-02518-w","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T07:02:07Z","timestamp":1683183727000},"page":"2886-2901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Abiy","family":"Agiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"AN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemmie","family":"Oluwatosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles V.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"1","key":"2518_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ehmc.2014.09.008","volume":"4","author":"J Theisen-Toupal","year":"2014","unstructured":"Theisen-Toupal J. Hypokalemia and hyperkalemia. Issue Hosp Med Clin. 2014;4(1):34.","journal-title":"Issue Hosp Med Clin"},{"issue":"7","key":"2518_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/01.smj.0000149407.51134.77","volume":"98","author":"HA Tran","year":"2005","unstructured":"Tran HA. Extreme hyperkalemia. South Med J. 2005;98(7):729\u201332. https:\/\/doi.org\/10.1097\/01.smj.0000149407.51134.77.","journal-title":"South Med J"},{"key":"2518_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.physiol.010908.163241","volume":"71","author":"JH Youn","year":"2009","unstructured":"Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol. 2009;71:381\u2013401. https:\/\/doi.org\/10.1146\/annurev.physiol.010908.163241.","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"2518_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/03007995.2018.1433141","volume":"34","author":"KA Betts","year":"2018","unstructured":"Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971\u20138. https:\/\/doi.org\/10.1080\/03007995.2018.1433141.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2518_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):S1\u201387. https:\/\/doi.org\/10.1016\/j.kint.2020.11.003.","journal-title":"Kidney Int"},{"issue":"5S","key":"2518_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"12","key":"2518_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139. https:\/\/doi.org\/10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"issue":"12","key":"2518_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360. https:\/\/doi.org\/10.1056\/NEJMoa011303.","journal-title":"N Engl J Med"},{"issue":"9069","key":"2518_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857\u201363.","journal-title":"Lancet"},{"issue":"9136","key":"2518_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/s0140-6736(98)04433-x","volume":"352","author":"P Ruggenenti","year":"1998","unstructured":"Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352(9136):1252\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(98)04433-x.","journal-title":"Lancet"},{"issue":"5","key":"2518_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1681\/ASN.V105997","volume":"10","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol. 1999;10(5):997\u20131006. https:\/\/doi.org\/10.1681\/ASN.V105997.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2518_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","volume":"32","author":"J Tamargo","year":"2018","unstructured":"Tamargo J, Caballero R, Delpon E. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther. 2018;32(1):99\u2013119. https:\/\/doi.org\/10.1007\/s10557-017-6767-5.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"2518_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40620-021-01070-6","volume":"35","author":"A Santoro","year":"2022","unstructured":"Santoro A, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Degli EL. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease. J Nephrol. 2022;35(2):463\u201372. https:\/\/doi.org\/10.1007\/s40620-021-01070-6.","journal-title":"J Nephrol"},{"key":"2518_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2023.01.002","volume":"258","author":"M Johnson","year":"2023","unstructured":"Johnson M, Morrison FJ, McMahon G, Su M, Turchin A. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. Am Heart J. 2023;258:49\u201359. https:\/\/doi.org\/10.1016\/j.ahj.2023.01.002.","journal-title":"Am Heart J"},{"issue":"18","key":"2518_CR15","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"2518_CR16","unstructured":"LOKELMA\u2122. Label and Prescribing Information. 2018."},{"issue":"6","key":"2518_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","volume":"14","author":"BS Spinowitz","year":"2019","unstructured":"Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798\u2013809. https:\/\/doi.org\/10.2215\/CJN.12651018.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2518_CR18","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","volume":"34","author":"T Yildirim","year":"2012","unstructured":"Yildirim T, Arici M, Piskinpasa S, et al. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3\u20135 in clinical practice: a safety concern? Ren Fail. 2012;34(9):1095\u20139. https:\/\/doi.org\/10.3109\/0886022X.2012.717478.","journal-title":"Ren Fail"},{"issue":"6","key":"2518_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/MAJ.0000000000000475","volume":"349","author":"S Shirazian","year":"2015","unstructured":"Shirazian S, Grant CD, Mujeeb S, et al. Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease. Am J Med Sci. 2015;349(6):510\u20135. https:\/\/doi.org\/10.1097\/MAJ.0000000000000475.","journal-title":"Am J Med Sci"},{"issue":"2","key":"2518_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/00325481.2019.1706920","volume":"132","author":"CP Kovesdy","year":"2020","unstructured":"Kovesdy CP, Gosmanova EO, Woods SD, et al. Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med. 2020;132(2):176\u201383. https:\/\/doi.org\/10.1080\/00325481.2019.1706920.","journal-title":"Postgrad Med"},{"issue":"11 Suppl","key":"2518_CR21","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212\u201320.","journal-title":"Am J Manag Care"},{"issue":"3","key":"2518_CR22","doi-asserted-by":"publisher","first-page":"e0213192","DOI":"10.1371\/journal.pone.0213192","volume":"14","author":"M Jun","year":"2019","unstructured":"Jun M, Jardine MJ, Perkovic V, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study. PLoS ONE. 2019;14(3):e0213192. https:\/\/doi.org\/10.1371\/journal.pone.0213192.","journal-title":"PLoS ONE"},{"issue":"2","key":"2518_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/14737167.2023.2161514","volume":"23","author":"CV Pollack Jr","year":"2023","unstructured":"Pollack CV Jr, Agiro A, Mu F, et al. Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study. Expert Rev Pharmacoecon Outcomes Res. 2023;23(2):241\u201350. https:\/\/doi.org\/10.1080\/14737167.2023.2161514.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02518-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:43:02Z","timestamp":1693302182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02518-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2518"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02518-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"2 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been revised due to correction in second author name.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}